Litcius/Paper detail

Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host

Caitlin A. Trottier, Beverly Wong, Rakhi Kohli, Cassidy Boomsma, Francis Magro, Sucharita Kher, Christina Anderlind, Yoav Golan

2022Clinical Infectious Diseases83 citationsDOIOpen Access PDF

Abstract

The management of patients with prolonged viral shedding and coronavirus disease 2019 symptoms remains unclear. Combining antivirals, as practiced in other infections, is theoretically advantageous. We present a case of persistent, symptomatic severe acute respiratory syndrome coronavirus 2 infection and associated organizing pneumonia that was successfully treated with an extended course of combination antiviral therapy.

Topics & Concepts

MedicinePneumoniaCoronavirusViral pneumoniaCoronavirus disease 2019 (COVID-19)ImmunologyViral sheddingAntiviral therapySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseVirologyRespiratory diseaseVirusInfectious disease (medical specialty)Internal medicineLungChronic hepatitisSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host | Litcius